SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Syngene helps biopharma companies accelerate large molecule therapies to market through integrated biologics CDMO services, with manufacturing facilities across the U.S. and India. With a GMP capacity of 50 KL in single-use bioreactors, featuring 500 L, 2000 L and 4000 L units designed to deliver economies of scale, Syngene offers innovative, flexible, and efficient solutions to its clientele.
